Two low-dose levonorgestrel intrauterine contraceptive systems (LNG-IUSs; total content 13.5 mg [average approx. 8 μg/24 hours over the first year; LNG-IUS 8] and total content 19.5 mg [average approx. 13 μg/24 hours over the first year; LNG-IUS 13]) have previously been shown to be highly effective (3-year Pearl Indices: 0.33 and 0.31, respectively), safe and well tolerated. The present subgroup analyses evaluated whether or not outcomes were affected by parity, age (18–25 vs 26–35 years), or body mass index (BMI, <30 vs ≥30 kg/m2).
Nulliparous and parous women aged 18‒35 years with regular menstrual cycles (21‒35 days) requesting contraception were randomized to 3 years of LNG-IUS 8 or LNG-IUS 13 use.
In the LNG-IUS 8 and LNG-IUS 13 groups, 1432 and 1452 women, respectively, had a placement attempted and were included in the full analysis set; 39.2%, 39.2% and 17.1% were 18–25 years old, nulliparous and had a BMI ≥30 kg/m2, respectively. Both systems were similarly effective regardless of age, parity or BMI; the subgroup Pearl Indices had widely overlapping 95% confidence intervals. Placement of LNG-IUS 8 and LNG-IUS 13 was easier (p < 0.0001) and less painful (p < 0.0001) in women who had delivered vaginally than in women who had not. The complete/partial expulsion rate was 2.2–4.2% across all age and parity subgroups and higher in parous than in nulliparous women (p = 0.004). The incidence of pelvic inflammatory disease was 0.1–0.6% across all age and parity subgroups: nulliparous and younger women were not at higher risk than parous and older women, respectively. The ectopic pregnancy rate was 0.3–0.4% across all age and parity subgroups. Across all age and parity subgroups, the 3-year completion rate was 50.9–61.3% for LNG-IUS 8 and 57.9–61.1% for LNG-IUS 13, and was higher (p = 0.0001) among older than younger women in the LNG-IUS 8 group only.
LNG-IUS 8 and LNG-IUS 13 were highly effective, safe and well tolerated regardless of age or parity.
Clinical trials.gov NCT00528112
Citation: Gemzell-Danielsson K, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, et al. (2015) The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. PLoS ONE 10(9): e0135309. https://doi.org/10.1371/journal.pone.0135309
Editor: Sharon Cameron, NHS lothian and University of Edinburgh, UNITED KINGDOM
Received: June 9, 2014; Accepted: December 23, 2014; Published: September 17, 2015
Copyright: © 2015 Gemzell-Danielsson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The study was funded by Bayer HealthCare Pharmaceuticals. The authors also acknowledge medical writing support in the development of the manuscript, provided by Chameleon Communications, with the financial support of Bayer HealthCare. The authors Thomas Schmelter, Sarah Rybowski and Kimberly Rosen are employees of Bayer HealthCare. Kimberly Rosen was involved in the design of the study and verified the data included in the manuscript, Thomas Schmelter was the study statistician and Sarah Rybowski verified the data included in the manuscript. In addition, they all contributed to the writing of the manuscript.
Competing interests: The authors of this manuscript have read the journal's policy and have the following competing interests: Kristina Gemzell-Danielsson occasionally serves on advisory boards and has been an invited speaker at scientific meetings for Bayer AG, MSD/Merck, HRA Pharma, ExcelGyn and Gideon Richter on an ad hoc basis. Her institution has received grants for conducting the Phase II and Phase III clinical trials of the 13.5 mg and 19.5 mg levonorgestrel intrauterine contraceptive systems. Dan Apter’s institution has received grants from Bayer Healthcare for conduct of the Phase II and Phase III trials of the 13.5 mg and 19.5 mg levonorgestrel intrauterine contraceptive systems. He has also taken part in advisory boards and has been an invited speaker at scientific meetings for Bayer AG, MSD/Merck, HRA Pharma, and Gideon Richter on an ad hoc basis. Brian Hauck’s institution has received grants for conduct of the Phase II and Phase III clinical trials of the 13.5 mg and 19.5 mg levonorgestrel intrauterine contraceptive systems. He has served on advisory boards and is currently a speaker for Merck, Bayer Healthcare and Pfizer. Thomas Schmelter and Sarah Rybowski are full-time employees of Bayer Pharma AG. Kimberly Rosen is a full-time employee of Bayer HealthCare Pharmaceuticals. Anita Nelson has received honoraria for serving on speakers’ bureaus and advisory boards for Bayer HealthCare. Her clinic has received grant funding for conduct of this Phase III study from Bayer HealthCare. Kristina Gemzell-Danielsson confirms that she is a PLOS ONE Associate Editor and this does not alter the authors' adherence to PLOS ONE editorial policies and criteria.
Although national and international guidance supports the use of intrauterine contraception (IUC) in a wide range of women, regardless of age and parity [1–4], IUC is used less frequently in younger and nulliparous women. In a US-based survey that analysed healthcare providers’ attitudes to providing IUC, more than 60% of providers reported they infrequently provided IUC to nulliparous women .
Bayer HealthCare has developed two low-dose levonorgestrel intrauterine contraceptive systems (LNG-IUSs); total content 13.5 mg (average approx. 8 μg/24 hours over the first year; hereafter referred to as LNG-IUS 8) and total content 19.5 mg (average approx. 13 μg/24 hours over the first year; hereafter referred to as LNG-IUS 13), designed to be potentially more suitable for women with either a tighter cervical canal or a smaller uterine cavity. Compared with LNG-IUS total content 52 mg (average approx. 20 μg/24 hours over the first year; hereafter referred to as LNG-IUS 20; Mirena), LNG-IUS 8 and LNG-IUS 13 have smaller T-frames (28 × 30 mm vs 32 × 32 mm) and smaller hormone reservoirs, allowing them to be placed using a smaller diameter placement tube (3.80 mm vs 4.75 mm or 4.4 mm, with the recently marketed EvoInserter).
In a Phase II study, LNG-IUS 8 and LNG-IUS 13 demonstrated good contraceptive efficacy over 3 years with no apparent dose–response, were well tolerated and were significantly easier and less painful to place compared with placement of LNG-IUS 20 using the 4.75 mm diameter placement tube . LNG-IUS 8 and LNG-IUS 13 subsequently underwent further evaluation in a Phase III study; the overall results of this study have been reported previously . Based on the results of these two studies, LNG-IUS 8 was approved by the US Food and Drug Administration (as Skyla) for up to 3 years of contraceptive use. In addition, LNG-IUS 8 was deemed ‘approvable’ by the Decentralized Procedure in the EU and was subsequently approved (as Jaydess) in most European countries, Canada and some countries in Latin America [8,9].
Here, we present post hoc subgroup analyses of Phase III data that evaluate the effect of age, parity and body mass index (BMI) on the efficacy of LNG-IUS 8 and LNG-IUS 13; the effect of age and parity on safety outcomes, continuation rates, reasons for discontinuation and user satisfaction; and the effect of parity on the ease and pain of placement.
Materials and Methods
This open-label, randomized Phase III study (clinical trials.gov; NCT00528112; https://clinicaltrials.gov/ct2/show/NCT00528112) was conducted at 138 study centres across 11 countries between August 2007 and June 2011. The protocol (see S1 Protocol) and its amendments were reviewed and approved by the independent ethics committee or institutional review board at each study site and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all participants before study entry.
The methodology and overall results have been published previously . The pertinent elements of the protocol were as follows: Healthy nulliparous and parous women aged 18–35 years (inclusive) with regular menstrual cycles (21–35 days) requesting contraception were recruited. Women were required to have uterine conditions considered by the investigating physician to be suitable for placement of an LNG-IUS, although no maximum or minimum uterine dimensions were specified and no screening failures were reported to be due to an investigator considering the uterus too small.
Subjects were randomized 1:1 to 3 years of treatment with either LNG-IUS 8 or LNG-IUS 13. Treatment assignment was blinded to participating women. However, it was not possible to blind investigators to randomization because of visible differences between LNG-IUS 8 and LNG-IUS 13 in the length of the hormone reservoir.
LNG-IUS 8 and LNG-IUS 13 were placed during the first 7 days of the woman’s menstrual cycle. Two placement attempts were permitted per woman and if both attempts failed, the subject was withdrawn from the study. The use of local anaesthesia, oral analgesics and cervical dilation was permitted at the discretion of individual investigators. After placement, ultrasound was used to confirm the ‘compliant’ positioning of the system (i.e. completely within the uterine cavity).
At the LNG-IUS placement visit, investigators rated the ease of placement (from their own perspective) as ‘easy’, ‘slightly difficult’ or ‘very difficult’, based on their own perception of what these terms meant. In addition, women rated their pain on placement as ‘none’, ‘mild’, ‘moderate’ or ‘severe’, again based on their own perception of what these terms meant.
All uterine perforations and ectopic pregnancies were to be reported as serious adverse events (SAEs). Complete or partial expulsions were to be reported as AEs. During the study, a protocol amendment in 2009 clarified the definition of a partial expulsion (LNG-IUS at least partially located in the cervical canal by ultrasound and/or partially visible in the vagina on clinical examination) and confirmed that it was not necessary to remove an LNG-IUS that was completely within the uterine cavity (not in the cervical canal) even if it was not in the fundal position.
Another protocol amendment in 2009 required that participating women were asked to complete a user satisfaction questionnaire either at the end of 3 years (those who completed 3 years of treatment) or at their final study visit (those who discontinued prematurely). Women rated their overall satisfaction with study treatment as: ‘very satisfied’, ‘somewhat satisfied’, ‘neither satisfied/dissatisfied’, ‘dissatisfied’ or ‘very dissatisfied’. For women who experienced bleeding while on treatment, satisfaction with their menstrual bleeding pattern was rated as: ‘very satisfied’, ‘somewhat satisfied’, ‘neither satisfied/dissatisfied’, ‘dissatisfied’ or ‘very dissatisfied’. For women who did not experience bleeding while on treatment, their satisfaction with their menstrual bleeding pattern was recorded as ‘not applicable’. When asked about their preference for use of contraception after the study, women answered from the following options: ‘continue with study treatment’, ‘use a different hormonal contraceptive’, ‘use a different contraceptive method’, ‘discontinue use of all types of contraception’ or ‘don’t know’.
The pregnancy rate was expressed as the Pearl Index (number of pregnancies per 100 woman-years; the primary efficacy variable). Pearl Index and the corresponding confidence interval (CI) calculations assumed that the number of pregnancies followed a Poisson distribution. The cumulative failure rate was also calculated using the Kaplan–Meier method. Exposure calculations were based on the time from LNG-IUS placement until expulsion/removal of the system, or the end of 3 years of use. Months during which women used concomitant contraception (e.g. condoms) or prohibited medications such as sex steroid hormones were subtracted from respective exposure times. If a pregnancy occurred during such a month, the pregnancy would have been considered but the month would have been subtracted from the exposure time. Women who had a failed placement attempt were assumed to have an exposure time of 1 day (because they were considered to have been briefly exposed during the placement attempt) and were included in the efficacy analysis. Pregnancies that occurred after LNG-IUS removal or known expulsion were not included in Pearl Index calculations.
Analyses included data from all randomized women for whom LNG-IUS placement was attempted (full analysis set), with the exception of the analysis of expulsion rates, which included only women who had had a successful placement. Subgroup analyses were performed to evaluate the effect of age, parity and BMI on the efficacy of LNG-IUS 8 and LNG-IUS 13; the effect of age and parity on safety outcomes, continuation rates, reasons for discontinuation and user satisfaction; and the effect of parity on the ease and pain of placement. P values for differences in outcomes between the subgroups were calculated using log rank tests and Fisher’s exact tests. All statistical tests were performed using SAS software.
As previously reported , the sample size for the study was calculated so that sufficient women were recruited to give, in both treatment groups, a Pearl Index (primary endpoint) with a two-sided 95% CI, such that the difference between the upper limit of the CI and the point estimate (expressed in pregnancies per 100 woman-years) did not exceed 1 for each considered year of treatment. However, it is difficult to evaluate power for post hoc subgroup analyses because this would require the determination of what constitutes a relevant difference for each outcome variable under consideration, before performing a power calculation for each of the subgroup analyses. Power analyses for the post hoc analyses were therefore not performed.
The study protocol and its amendments were approved by the following ethics committees and institutional review boards (IRB):
Comité Independiente Etica para Ensayos Farmacologia Clinica "Prof. Dr. Luis Maria Zieher", Buenos Aires; Comité de Ética Julio Cesar Maiztegui, Santa Fe; Hospital Bernardino Rivadavia Comité de Bioética, Buenos Aires.
Biomedical Research Ethics Board, University of Manitoba, Winnipeg; Ethics Review Board, Queens University, Kingston; Office of Research Ethics, University of Western Ontario; Conjoint Health Research Ethics Board, University of Calgary, Calgary.
Comité de Etica Servicio de Salud Metropolitano Norte, Santiago; Servicio de Salud Metropolitano Oriente Comité Etico Cientifico, Providencia.
Medical Research Council EC for Clinical Pharmacology, Budapest; Regional Human Medical Research Ethical Committee, University of Szeged; Institutional Ethics Committee, Bács-Kiskun County Hospital, Kecskemét; Institutional Research Ethics Committee, Bekes County Hospital “Rethy Pal”, Bekescsaba.
Comité de Bioética de la Facultad de Medicina de Torreón, Torreón; Comité de Etica, Hospital Integral de la Mujer del Estado De Sonora, Hermosillo; Comité Bioético para la Investigación Clinica S. C., Mexico D. F.; Comité de Etica de la Facultad de Medicina, Hospital Universitario “José Eleuterio González”, Monterrey.
Independent Investigational Review Board, Inc., Florida; IRB, Columbia University Medical Center, NY; Chesapeake IRB, Columbia, Maryland; Scripps Cancer Center IRB, La Jolla, California; Research and Clinical Trials Administration Office, Rush University Medical Center, Chicago, Illinois; IRB, Oregon Health and Science University, Portland, Oregon; IRB University of Cincinnati, Ohio; Western University IRB, Washington, USA; John F Wolf Human Subjects Committee, LA Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California; Crescent City IRB, New Orleans, Louisiana; Independent IRB, 1550 Sawgrass Corporate Parkway, Florida.
The disposition of women in the full analysis set has previously been reported . The distribution of women among the subgroups analysed is shown in Table 1 (S1 Data). Among 2884 subjects in the full analysis set, 39.2% were nulliparous and 51.5% had never had a vaginal delivery. The maximum depth to which a woman’s uterus sounded was 10 cm among nulliparous women and 11 cm among parous women. However, no maximum or minimum uterine dimensions were specified in the eligibility criteria.
The first-year and 3-year unadjusted Pearl Indices and the unadjusted Kaplan–Meier estimates for the first-year and 3-year cumulative failure rates for LNG-IUS 8 and LNG-IUS 13 are shown in Tables 2 and 3 (S1 Data). These efficacy outcomes were not significantly affected by women’s age, parity status or BMI (95% CIs overlapped).
Placement success rates, use of cervical dilation for placement and administration of pain medications for placement, by parity status, are summarized in Table 4 (S2 Data). Ease of placement from the investigator’s perspective is shown in Fig 1A and pain on placement from the woman’s perspective is summarized in Fig 1B. Because LNG-IUS 8 and LNG-IUS 13 had identical T-frame dimensions and were placed using identical placement tubes, these data were analysed for both treatment groups combined.
Placement was successful at the first attempt in at least 95% of women, regardless of parity. Overall, allowing up to two attempts per woman, a successful placement was achieved in 2871 of 2884 women (99.5%). Placement was unsuccessful in a total of 13 women; this included nulliparous and parous women. Placement was performed without cervical dilation in most women (>90%), regardless of parity. Nulliparous women more frequently received local anaesthesia and oral analgesia compared with parous women; however, pain medications were mostly administered prophylactically (i.e. before the procedure), rather than reactively if the procedure proved painful (Table 4).
Placements were generally easier from the investigator’s perspective in women who had previously had a vaginal delivery than in nulliparous women or parous women who had delivered by Caesarean section only (no vaginal deliveries) (p < 0.0001 for overall difference). Nevertheless, placement was rated as ‘easy’ in more than 80% of women who had not had a vaginal delivery (Fig 1A).
Parous women generally reported less placement-related discomfort than nulliparous women (p < 0.0001 for overall difference). Nevertheless, among nulliparous women, 41.8% reported no more than ‘mild’ pain and 84.5% reported no more than ‘moderate’ pain. Women who had previously had a vaginal delivery generally experienced less discomfort compared with nulliparous women and women who had had a Caesarean section delivery only (Fig 1B; p < 0.0001 for overall difference).
In both treatment groups combined, the Kaplan–Meier cumulative probability of complete/partial expulsion was higher in parous women than in nulliparous women (p = 0.0002) (Table 5) and slightly higher in younger women (aged 18–25 years) than in women aged 26–35 years (Table 5), although the difference was not statistically significant (p = 0.07). The crude complete/partial expulsion rates for parous women and for younger women (aged 18–25 years) over up to 3 years were 4.2% and 3.9%, respectively. The risk of expulsion was greatest in the first 12 months after placement, regardless of parity status or age category (Table 5).
One partial uterine perforation was reported during the study (a case of myometrial embedment with LNG-IUS 13 in a nulliparous woman); the IUS was removed vaginally.
Over up to 3 years of LNG-IUS 8 or LNG-IUS 13 use, nulliparous women were at no higher risk of pelvic inflammatory disease (PID) than their parous counterparts (crude PID incidence: 0.1% vs 0.6%, respectively) and younger women aged 18–25 years were no more likely to be diagnosed with PID than older women aged 26–35 years (crude incidence: 0.2% vs 0.6%, respectively) (Table 5).
The crude incidence of ectopic pregnancy over up to 3 years of LNG-IUS 8 or LNG-IUS 13 use was 0.3–0.4% across all age and parity subgroups (Table 5). Of the 20 pregnancies that occurred during the study, 10 (50%) were ectopic.
The percentages of women who completed 1 year and 3 years of treatment with LNG-IUS 8 or LNG-IUS 13 were favourable across all age and parity subgroups (Table 6). The Year 1 completion rate was significantly higher among parous women than nulliparous women in both treatment groups (p = 0.043 and p = 0.009 in the LNG-IUS 8 and LNG-IUS 13 groups, respectively). In the LNG-IUS 8 system group, the Year 1 and 3-year completion rates were significantly higher among women aged 26–35 years than among women aged 18–25 years (p = 0.0011 and p = 0.0001, respectively) (Table 6).
The percentages of women who discontinued study treatment before the end of 3 years for reasons unrelated to AEs were favourable in both treatment groups and across all age and parity subgroups. In the LNG-IUS 8 group, the 3-year discontinuation rate for reasons unrelated to AEs was significantly higher among women aged 18–25 years than in those aged 26–35 years (p = 0.0281) (Table 6). The desire to become pregnant before the end of the 3-year study period was a major reason for premature discontinuation in both treatment groups (Table 6). In both treatment groups, there were slightly more discontinuations owing to AEs among nulliparous women than among parous women (the difference was statistically significant for LNG-IUS 8 only; p = 0.0025) and among women aged 18–25 years than those aged 26–35 years (the difference was statistically significant for LNG-IUS 8 only; p = 0.0185) (Table 6).
Rates of premature discontinuation (before 3 years) owing to change in menstrual bleeding pattern (including development of amenorrhoea) were approximately 5% in both treatment groups, with no significant differences across the age and parity subgroups (range 3.4–5.7%) (Table 6). In total, 2 subjects reported that they discontinued due to amenorrhoea.
Overall, 2116 of 2884 women in the full analysis set completed a user satisfaction questionnaire either at the end of 3 years (those who completed the study) or at their last study visit (those who discontinued prematurely): 802 and 1314 were nulliparous and parous, respectively; 784 and 1332 were 18–25 and 26–35 years of age, respectively. Across all age and parity subgroups, >90% of women were either ‘very satisfied’ or ‘somewhat satisfied’ with LNG-IUS 8 and LNG-IUS 13, >70% of women were either ‘very satisfied’ or ‘somewhat satisfied’ with their menstrual bleeding pattern during use of LNG-IUS 8 and LNG-IUS 13, and >70% of women reported they would prefer to continue their use of study treatment after the study (Table 7).
The post hoc subgroup analyses reported here confirm that LNG-IUS 8 and LNG-IUS 13 were similarly effective regardless of the age, parity status or BMI of the user, demonstrated by first year and 3-year Pearl Indices and Kaplan–Meier cumulative failure rates for the subgroups that had widely overlapping 95% CIs. However, a limitation of the analysis according to BMI was that there were relatively few women (n = 494) in the higher BMI (≥30 kg/m2) subgroup, hence the wide 95% CIs for the first year and 3-year Pearl Indices and cumulative failure rates for this subgroup.
There is the perception among some healthcare providers that IUC is much more difficult to place in nulliparous women than in women who had already had a child . However, parous women who have had elective Caesarean section deliveries only (and not laboured at all) may be considered to be similar to nulliparous women with regard to the tightness of their cervical canals. Investigators rated the placement of LNG-IUS 8 and LNG-IUS 13 as ‘easy’ in most women, regardless of parity. However, placement was rated by investigators as ‘easy’ in a higher percentage of women who had previously had a vaginal delivery (94.5%) compared with those who had had Caesarean section deliveries only (87.7%; it was not known when during the course of pregnancy or labour Caesarean section deliveries were performed) or nulliparous women (84.2%). However, a placement that is rated as ‘easy’ the investigator is not necessarily considered ‘easy’ or ‘pain-free’ by the woman. Investigators rated placement as ‘very difficult’ in only 2.1% of nulliparous women and 1.4% of women who had had Caesarean section deliveries only.
In total, 41.8% and 84.5% of nulliparous women reported their pain on placement as no more than ‘mild’ and no more than ‘moderate’, respectively. However, parous women generally reported less placement-related discomfort than their nulliparous counterparts and, among parous women, those who had had a vaginal delivery generally reported less discomfort than those who had had Caesarean section deliveries only: no more than ‘mild’ pain was reported by 41.8% of nulliparous women, 72.8% of parous women who had had Caesarean section deliveries only, and 81.9% of parous women who had previously had a vaginal delivery.
The analysis of placement-related pain did not take into account that more nulliparous women received pre-placement local anaesthesia (14.5%) and analgesia (48.6%) compared with the parous subgroups. However, these interventions are readily available and commonly used in routine medical practice . In addition, the reporting of ease of placement and pain of placement was subjective; investigators may have varied in what they considered an ‘easy’ placement and women may have varied in what they considered to be ‘mild’, ‘moderate’ or ‘severe’ pain.
Placement was performed without cervical dilation in 90.8% of nulliparous women, 93.8% of women who had had Caesarean section deliveries only and 97.6% of women who had previously had a vaginal delivery. In a retrospective study evaluating ease of placement and clinical performance of LNG-IUS 20 (Mirena) in nulligravid women, a similar proportion of nulligravid women (92.3%) underwent placement without cervical dilation .
The incidences of at least partial expulsion, uterine perforation, PID and ectopic pregnancy were low across all age and parity subgroups. Concern exists in the literature regarding an increased risk of expulsion in nulliparous women . However, the results from this study reinforce evidence from other studies showing that nulliparous women are at no higher risk of expulsion than parous women [14,15].
Younger women are generally considered to be at higher risk of contracting sexually transmitted infections compared with older women and therefore might be expected to have a higher risk of developing PID, particularly in this study, in which condom use was not encouraged. However, no difference in the incidence of PID between the older and younger women was observed.
The absolute incidence of ectopic pregnancy was low across all age and parity subgroups in both treatment arms. Furthermore, the absolute incidence of ectopic pregnancy for the LNG-IUS 8 and LNG-IUS 13 groups combined (0.13–0.22 per 100 woman-years across all age and parity subgroups) was within the reported range for oral contraceptives (absolute incidence: 0.07–1.99 per 100 woman-years for combined oral contraceptives; 0.3–2.0 per 100 woman-years for progestogen-only pills) .
One-year and 3-year completion rates were favourable for both LNG-IUS 8 and LNG-IUS 13 regardless of age or parity, reflecting high levels of satisfaction with study treatment across all subgroups. The 3-year completion rates for LNG-IUS 8 and LNG-IUS 13 also compare favourably with 3-year continuation rates for combined oral contraceptives. The number of women who prematurely discontinued owing to a desire for pregnancy was similar across all age and parity subgroups. Importantly, few women discontinued because of changes in menstrual bleeding patterns, regardless of age or parity. The percentages of women who discontinued because of AEs were favourable in both treatment groups and across all age and parity subgroups. However, in the LNG-IUS 8 group, significantly more nulliparous women than parous women and significantly more women aged 18–25 years than women aged 26–35 years discontinued because of AEs, whereas no significant difference by parity or age was observed in the LNG-IUS 13 group. The reason for this dose difference is unclear; however, it could be a chance finding between non-randomized parity and age subgroups.
Overall, these subgroup analyses demonstrate that LNG-IUS 8 and LNG-IUS 13 are highly effective, safe, well tolerated and associated with high levels of user satisfaction and favourable continuation rates, regardless of age or parity. These data refute the misconceptions held by some healthcare providers that IUC is not suitable for younger women or nulliparous women and add to the scientific evidence supporting the more widespread use of IUC among these groups.
S2 Data. Post Hoc Analyses of Discontinuations, Insertion and User Evaluation Outcomes.
We thank the participating investigators and coordinators at the 138 study centres and Pia Rautiainen and Teija Tervomaa for management of the study. We also acknowledge medical writing support in the development of the manuscript, which was provided by Sonya Haslam of Chameleon Communications, with the financial support of Bayer HealthCare.
Conceived and designed the experiments: KR. Performed the experiments: KGD DA BH AN. Analyzed the data: TS SR KR KGD DA BH AN. Wrote the paper: TS SR KR KGD DA BH AN.
- 1. Lyus R, Lohr P, Prager S (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81: 367–371. pmid:20399942
- 2. World Health Organization (2010) Medical eligibility criteria for contraceptive use: fourth edition. Available: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Accessed 11 May 2015.
- 3. Centers for Disease Control and Prevention (2010) MMWR: Sexually transmitted diseases treatment guidelines 2010. Available: http://www.cdc.gov/std/treatment/2010/pid.htm. Accessed 21 October 2014.
- 4. Faculty of the Royal College of Obstetricians and Gynaecologists (2009) UK medical eligibility for contraceptive use. Available: http://www.fsrh.org/pdfs/UKMEC2009.pdf. Accessed 27 July 2015.
- 5. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA (2012) Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 119: 762–771. pmid:22433340
- 6. Gemzell-Danielsson K, Schellschmidt I, Apter D (2012) A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 97: 616–622. pmid:22222193
- 7. Nelson AL, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K et al. (2013) Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 122: 1205–1213. pmid:24240244
- 8. Bayer HealthCare Pharmaceuticals Inc. (2012) Cost of unintended pregnancy: model technical report—UK.
- 9. Bayer HealthCare Pharmaceuticals Inc (2013) Skyla® Prescribing Information.
- 10. Black K, Lotke P, Buhling KJ, Zite NB (2012) A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women. Eur J Contracept Reprod Health Care 17: 340–350. pmid:22834648
- 11. Gemzell-Danielsson K, Mansour D, Fiala C, Kaunitz AM, Bahamondes L (2013) Management of pain associated with the insertion of intrauterine contraceptives. Hum Reprod Update 19: 419–427. pmid:23670222
- 12. Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I (2011) Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 84: e11–e16. pmid:22018132
- 13. Prager S, Darney PD (2007) The levonorgestrel intrauterine system in nulliparous women. Contraception 75: S12–S15. pmid:17531602
- 14. Veldhuis HM, Vos AG, Lagro-Janssen AL (2004) Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract 10: 82–87. pmid:15534571
- 15. Madden T (2010) Rates of continuation and expulsion of intrauterine contraception at 12 months in nulliparous and adolescent women. Contraception 82: 187–188.
- 16. Larimore WL, Stanford JB (2000) Ectopic pregnancy with oral contraceptive use has been overlooked. BMJ 321: 450.